Literature DB >> 15541960

Interpretation of expression-profiling results obtained from different platforms and tissue sources: examples using prostate cancer data.

G Chiorino1, F Acquadro, M Mello Grand, S Viscomi, R Segir, M Gasparini, P Dotto.   

Abstract

The analysis of expression signatures is a powerful tool for the classification of cancer and other tissue samples. Several protocols and platforms are available on the market, and these lead to both confirmatory and complementary results. We review the main processing techniques for cross-platform comparisons and the different tissue sources for cancer profiling. Some examples and the cross-interpretation of bibliographic data related to prostate cancer are also presented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541960     DOI: 10.1016/j.ejca.2004.07.029

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

Review 1.  Genomics of prostate cancer: is there anything to "translate"?

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2005-12-31       Impact factor: 3.201

2.  Cross platform microarray analysis for robust identification of differentially expressed genes.

Authors:  Roberta Bosotti; Giuseppe Locatelli; Sandra Healy; Emanuela Scacheri; Luca Sartori; Ciro Mercurio; Raffaele Calogero; Antonella Isacchi
Journal:  BMC Bioinformatics       Date:  2007-03-08       Impact factor: 3.169

3.  Storing, linking, and mining microarray databases using SRS.

Authors:  Antoine Veldhoven; Don de Lange; Marcel Smid; Victor de Jager; Jan A Kors; Guido Jenster
Journal:  BMC Bioinformatics       Date:  2005-07-27       Impact factor: 3.169

4.  AP-2alpha regulates migration of GN-11 neurons via a specific genetic programme involving the Axl receptor tyrosine kinase.

Authors:  Francesca Orso; Richard Jäger; Raffaele Adolfo Calogero; Hubert Schorle; Piero Sismondi; Michele De Bortoli; Daniela Taverna
Journal:  BMC Biol       Date:  2009-05-22       Impact factor: 7.431

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.